Danimarca - danese - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - captopril - tabletter - 25 mg

Danimarca - danese - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - captopril - tabletter - 25 mg

Unione Europea - danese - EMA (European Medicines Agency)

qbiotics netherlands b.v. - tigilanol tiglate - tigilanol tiglate - hunde - til behandling af ikke-resectable, ikke-metastatisk (der iscenesættelse) subkutan mast celle tumorer er placeret på eller distalt for den albue eller haseleddet, og ikke-resectable, ikke-metastatisk kutan mast celle tumorer hos hunde.

Unione Europea - danese - EMA (European Medicines Agency)

novo nordisk a/s - somapacitan - vækst - hypofysiske og hypotalamiske hormoner og analoger - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children  aged 3  years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).

Unione Europea - danese - EMA (European Medicines Agency)

amarin pharmaceuticals ireland limited - icosapent ethyl - dyslipidæmi - lipid modificerende midler - indicated to reduce cardiovascular risk as an adjunct to statin therapy.

Danimarca - danese - Lægemiddelstyrelsen (Danish Medicines Agency)

baxalta innovations gmbh - koagulationsfaktor ii, humant, koagulationsfaktor ix, humant, koagulationsfaktor vii, humant, koagulationsfaktor x, humant, protein c, human - pulver og solvens til injektionsvæske, opløsning - 500 ie

Danimarca - danese - Lægemiddelstyrelsen (Danish Medicines Agency)

nordic prime aps - hydrochlorthiazid, lisinoprildihydrat - tabletter - 20+12,5 mg

Unione Europea - danese - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastiske midler - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Unione Europea - danese - EMA (European Medicines Agency)

serb sas - glucarpidase - metabolic side effects of drugs and substances - alle andre terapeutiske produkter - voraxaze is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity.

Danimarca - danese - Lægemiddelstyrelsen (Danish Medicines Agency)

elanco gmbh - mycoplasma hyopneumoniae, stamme nl1042 (inaktiveret) - injektionsvæske, emulsion - 4,5-5,2 log10/dosis - svin